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Summary 
In multiple myeloma (MM), an incurable B-cell neoplasm, mutation or deletion of p53 is rarely detected at 
diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence that miR-192, 194 and 215, 
which are down-regulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 
and then modulate MDM2 expression. Furthermore, ectopic re-expression of these miRNAs in MM cells 
increases the therapeutic action of MDM2 inhibitors in vitro and in vivo by enhancing their p53-activating 
effects. In addition, miR-192 and 215 target the IGF pathway, preventing enhanced migration of plasma 
cells into bone marrow. The results suggest that these miRNAs are positive regulators of p53 and that their 
down-regulation plays a key role in MM development. 
Significance 
Therapeutic activation of p53 may be particularly appropriate for treatment of the ∼50% of hematopoietic 
malignancies with intact TP53. We describe a signaling pathway in which miR-192, 194 and 215 are 
regulators of the MDM2/p53 auto regulatory loop, controlling the balance between p53 and MDM2 
expression. Hypermethylation of the miR-194-2-192 cluster promoter in MM cell lines suggests that 
epigenetic down-regulation of these miRNAs, which leads to increased MDM2 mRNA and protein 
expression, decreases the ability of p53 to down-modulate MDM2 expression, thus tipping the regulatory 
loop in favor of MDM2. Exploring these miRNAs as enhancers in the pharmacological activation of the p53 
pathway in MM cells might open avenues for miRNA-targeted therapies and MM treatment. 
Introduction 
The tumor suppressor p53 is frequently inactivated by mutations or deletions in cancer. p53 acts as a 
potent transcription factor and can be activated in response to diverse stresses, leading to induction of cell-
cycle arrest, apoptosis or senescence (Junttila et al., 2009; Xue et al., 2007). Although regulation of the p53 
pathway is not fully understood at the molecular level, it has been well established that activated p53 
suppresses cancer progression, underlining why cancer cells have developed multiple mechanisms to 
disable p53 function (Danovi et al., 2004; Ventura et al., 2007). In human tumors that retain wild-type (WT) 
p53 (Junttila et al., 2009; Lane, 2001) p53 can be antagonized by murine double minute 2 (MDM2), a 
negative regulator of p53 that is also overpriced in many human tumors, offering a therapeutic strategy 
(Dickens et al., 2009; Brown et al., 2009). It has been reported that inhibiting MDM2 expression can re-
activate p53 in cancer cells, leading to their demise (Dickens et al., 2009; Saha et al., 2010). 
TP53 mutation is rarely detected at diagnosis in many hematological cancers such as multiple myeloma 
(MM), acute myeloid leukemia, chronic lymphocytic leukemia and Hodgkin's disease (HD). Thus, numerous 
reports have shown that therapeutic induction of p53 might be particularly suitable for the treatment of 
hematological malignancies (Saha et al., 2010). Among them, multiple myeloma (MM) is a currently 
incurable plasma cell proliferative disorder that results in considerable morbidity and mortality (Kuehl et 
al., 2002; Fonseca et al., 2009). MM develops from a benign condition called monoclonal gammopathy of 
undetermined significance (MGUS) (Weiss et al., 2009). Individuals with MGUS often remain stable for 
years and do not require treatment. However, for unknown reasons, this benign condition can evolve into 
MM at a rate of ∼1% per year, with some MMs developing after many years (Kuehl et al., 2002; Fonseca et 
al., 2009). 
In MGUS and in the majority of newly diagnosed MM cases TP53 is WT (Kuehl et al., 2002; Chng et al., 
2007) and the protein is rarely detectable (Stuhmer et al. 2006). Interestingly, in MM cells, expression of 
p53 protein levels can be rescued by antagonizing MDM2. Several reports have focused on the p53-
mediated apoptotic pathway, upon endogenous p53 protein re-expression by the small-molecule MDM2 
antagonists (Nutlins) and target genes wich may be involved in p53-dependent apoptosis in MM cells have 
been identified (Stuhmer et al. 2006). 
MicroRNAs are an abundant class of short, non protein-coding RNAs that mediate the regulation of target 
genes posttranscriptionally and that have emerged as master regulators in diverse physiologic and 
pathologic processes (Bartel, 2004), and oncogenesis (Croce, 2008). Recently, microRNAs (miRNAs) have 
been reported to be directly transactivated by p53 (He et al, 2007). miRNAs have also been shown to target 
p53 and/or components of p53 regulatory pathways, thereby directly and/or indirectly affecting its 
activities (Park et al., 2009; Zhang et al., 2009). We previously published the global miRNA–expression 
profiles of MM and MGUS, and contrasted these profiles with those of normal plasma cells (PCs) (Pichiorri 
et al., 2008). The findings defined a miRNA signature related to expression and regulation of proteins 
associated with malignant transformation of PCs, such as p53 (Pichiorri et al., 2008). We have now 
examined the regulation and functional roles of miRNAs in MM development using small-molecule 
inhibitors of MDM2. 
Results 
Identification of p53-regulated miRNAs in MM 
To determine if miRNAs are regulated by p53 in MM cells, we performed custom microarray analysis with 
an expanded set of probes capable of assaying the expression of more than 500 human miRNAs. Two 
approaches to compare the effect of p53 level on miRNA expression were used. We first assessed a specific 
signature associated with the presence of WT TP53 in MM cell lines as shown in Figure 1A and Table S1. Six 
MM cell lines were used in the analyses: MM1s, NCI-H929 and KMS28BM which retain and express WT 
TP53; RPMI-8226, U266 with mutant TP53; and JJN3 that do not express TP53 mRNA. Western blot analysis 
of these cells shows their p53 and MDM2 steadystate protein levels respectively (Figure S1A). Genomic and 
cDNA sequence analyses confirmed the presence of WT TP53 cells in association with higher MDM2 mRNA 
expression (Figure S1B). Several differentially expressed-miRNAs were identified (Table S1). Some of these 
miRNAs, such as those of miR-34 family, have been found to be associated with p53 status in other human 
malignancies (Hermeking et al., 2010). In the second approach, we performed miRNA microarray analysis in 
MM1s cells treated with or without Nutlin-3a (10 μM), a small-molecule inhibitor of MDM2 (Figure 1B). In 
response to Nutlin-3a treatment, we identified expression of distinct miRNAs associated with p53 
activation (Figure 1B. Table S2). Only two miRNAs were up-regulated in both analyses: miR-34a and miR-
194 (Figure 1A, B; Table S1, S2). These results not only confirm up-regulation of miR-34a as a function of 
wild-type (WT) p53 status (He et al., 2007) but also point to strong up-regulation of miR-194 by p53 (Table 
S1, S2; Figure 1A,B). The significant up-regulation of miR-192 and miR-215 after p53 re-expression through 
Nutlin-3a treatment is especially interesting because they are located, together with miR-194, in two 
related microRNA clusters, the miR-194-2-192 cluster at 11q13.1 and the miR-215-194-1 cluster at 1q41.1 
(Table S2), and have the same seed sequence. Genomic locations of these two clusters have been reported 
to be important for MM (Fonseca et al., 2009). miR-194 also has the same mature sequence regardless its 
expression cluster and miRNAs of the same cluster are usually expressed together (Garofalo et al., 2009; 
Ventura et al., 2008). 
 
Figure 1 
 
 
Identification of p53-regulated miRNAs in MM cells 
p53 induces the expression of miR-192, 194 and 215 
To confirm the microarray data, we first tested by q-RT-PCR for the presence of miR-34a, miR-194 and its 
cluster associate, miR-192 and 215, in WT TP53 compared to Mut TP53 cells (Figure S1C). WT TP53 cells 
retained higher expression of miR-34a, miR-194 and miR-192 (Figure S1C), but did not show expression of 
miR-215, suggesting that the 11q13.1 miR-194-2-192 cluster is associated with WT TP53 status in MM cells. 
To determine the kinetics of p53 activation, we treated MM 1s cells with 10 μM Nutlin-3a for different 
duration of time. p53 was barely detectable by immunoblotting at 6hr but increased after 12, 18 and 24 hrs 
of treatment and remain constant at 30-36 hrs (Figure 1C). The induction of p53 was also associated with 
MDM2 accumulation, p21 expression and c-MYC down regulation after 12 hrs of treatment (Figure 1C). The 
expression of p21-encoding CDKN1A, a p53 target gene, was also assessed by RT-PCR (Figure 1D). By 
northern blot and qRT-PCR analysis, we also studied the kinetics of miRNA activation during p53 up-
modulation in MM 1s cells. The kinetics of miR-34a, miR-194, miR-192 and miR-215 expression (Figure 1E) 
were directly correlated with p53 protein up-regulation and p21 activation (Figure 1C,D), while for miR-15 
and miR-29a/b the dynamics of expression appeared more related to down-regulation of their repressor c-
MYC as expected (Chang et al., 2008) (Figure S1D,S1E, Figure 1D), than to p53 activation. To confirm the 
responsiveness of these miRNAs to p53, cell lines with varying TP53 status were treated with Nutlin-3a or 
vehicle (DMSO), followed by qRT-PCR to monitor miRNA levels upon p53 activation (Figure S1F-S1K). 
Induction of miR-34a, miR-192, miR-215 and miR-194 was detected only in the cell lines treated with 
Nutlin-3a and harboring WT TP53 (p<0.001, Figure S1). Next, we analyzed induction of these miRNAs, by 
Nutlin-3a in freshly isolated CD-138+ PCs (Figure S1L), from 8 bone marrow aspirates of MM patients. Two 
samples (Pt-1 and Pt-2) exhibited TP53 deletion by FISH analysis, while 6 (Pt-3 to Pt-8) retained TP53 genes 
(Table S3). We detected induction of p53, miR-34a, 192, 194, 215 after 12 hrs of Nutlin-3a treatment 
(Figure S1M-S1O) in TP53 WT samples, in association with different levels of CDKN1A mRNA activation 
(Figure S1O). Furthermore, to determine if these miRNAs are relevant in MM pathogenesis, we analyzed 
the expression of miR-194, 192 and 215 in a panel of CD138+ PCs obtained from newly diagnosed MM 
patients (n=33), MGUS (n=14) patients and normal donors (n=4) (Table S3) by qRT-PCR (Figure 1F-1H). 
Through Kruskal-Wallis analysis we found that these clusters of miRNAs are consistently down-regulated in 
MM samples (p<0.001) compared to MGUS samples. 
Identification of the p53 core element in the pri-miR-192-194-2 promoter at 11q13.1 
To determine if p53 is directly involved in the transcriptional regulation of miR-194-2-192 and miR-215-194-
1 clusters, we analyzed the cluster promoter regions. The upstream genomic region close to the 
transcription start site (TSS) (+1) (Hino et al., 2008) of pri-miR-194-2-192 contains several highly conserved 
regions among human, mouse, rat, and dog sequences (from −162 to +21 with respect to the TSS). To 
identify the promoter region responsive to p53 re-expression, we constructed reporter plasmids carrying 
various genomic sequences around the TSS of the pri-miR-194-2-192 cluster and subjected them to 
luciferase assay (Figure 2A). Bioinformatics search identified a previously reported high score p53 
consensus site between -900/-912 bp (Sinha et al., 2008; Song et al., 2008), however this site was not 
functional for p53 activation since luciferase reporter constructs excluding this region retained full activity 
(P3-P7) (Figure 2A). The region from -245 to +186 bp (P7) had promoter activity comparable to that of the 
longest regions in MM cells after forced expression of p53 (Figure 2A), but regions from -125 to +186 bp 
(P8) and -912 to -245 bp (P10) did not. We identified a p53-responsive element between -245 and -125 bp 
(Figure 2B) because the construct excluding this region was not affected by p53 expression (Figure 2A). 
Since conserved regions in a given gene promoter are expected to contain regulatory elements, we focused 
on the highly conserved region controlling luciferase activity, the region between -161 and -135 bp. 
Luciferase assay using a construct mutated for each C and G contained in the two decamers of the 
hypothetical El-Deiry consensus sequence revealed that this non predicted and previously unpublished 
region is critical for p53 transcriptional activation of the pri-miR-194-2-192 cluster (Figure 2B). Indeed, we 
found that endogenous p53 directly interacts with the core element of the pri-miR-194-2 promoter in 
MM1s cells, as demonstrated by CHIP assay after 12 hr of Nutlin-3a treatment (Figure 2C). As a positive 
control, we used the p53 consensus site on the miR-34a promoter , while a nonspecific sequence served as 
negative control (Figure 2C). Ectopic-expression of p53 activated the promoter of both members of the pri-
miR-194-2-192 cluster in MM1s cells (Figure 2D). MDM2 siRNA after p53 re-expression in MM1s cells led to 
higher relative luciferase activity and thus confirmed its dependence on p53 re-activation. Taken together, 
these data suggest that p53 is a key transcriptional activator of pri-miR-194-2 through directly binding to 
the core promoter element (Figure 2D). We also attempted to identify the promoter and primary transcript 
of miR-215-194-1 on chromosome 1q41.1, but could not identify the primary transcript initiation point by 
3′ and 5′ RACE and PCR amplification of the putative transcribed sequences (EST), however we confirmed 
the previously published consensus site for p53 by CHIP analysis (Figure S2). 
 
Figure 2 
 
miR-194-2-192 cluster is induced following p53 activation 
miR-192, 194 and 215 affect p53-dependent MM cell growth 
To examine the relevance of p53-mediated regulation of miR-192, 194 and 215 in MM, we first tested 
whether reintroduction of these miRNAs affected the biology of MM cells. Previous studies (Georges et al., 
2008; Braun et al., 2008) showed that such reintroduction induced expression of p21 in different cancer cell 
lines which carried WT TP53, with a consistent G0/G1 arrest and p53 protein expression. The molecular 
mechanism of p53 re-expression remained elusive. To confirm this effect in our model, miR-192, miR-194 
and miR-215 were introduced into transfection in WT TP53 cell lines (MM1s, NCI-H929 and KMS28BM), as 
well as cells with mutated TP53 (RPMI-8226), followed by detection of TP53 and mRNAs of target genes 
CDKN1A and MDM2, by RT-PCR analysis (Figure S3). We found consistent re-expression of CDKN1A in TP53 
WT cells (Figure S3A) after transfection, but did not detect any increase in TP53 mRNA (Figure S3B). Using 
MTS assay, we observed significant growth arrest in the cells transfected with miR-192, 215 and a less 
significant arrest with miR-194 in MM cells carrying WT TP53 (Figure 3A-3C), as compared to scrambled 
sequences. By contrast, we did not detect this effect in RPMI-8226 cells (Figure 3D) expressing mutant 
TP53. Next, we determined if p53-responsive miRNAs interfere with the clonogenic survival of MM cells. 
MM cells were lentivirustransduced with miR-192, miR-215, miR-194 and miR-34a, miR-192 and 215 in WT 
p53 cells suppressed colony formation to an extent comparable to miR-34a, which was used as an internal 
control. Of note, miR-194 was less effective than miR-215 and miR-192. These miRNAs did not suppress 
colony formation in RPMI-8226 (Figure 3E and 3F) or U266 cells (unpublished data), while miR-34a did 
exhibit colony suppression in these mutant TP53 cells, confirming its p53 independent apoptotic action 
(Hermeking et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3 
 
miR-192-194-215 induce decrease of proliferation and cell cycle arrest in WT TP53 MM cells 
To further explore the p53-dependent mechanism(s) of miR-192, 215 and 194 interferences with cell 
growth and colony formation, we used flow cytometry to determine if their expression affects progression 
through the cell cycle. We noted that in the two WT TP53 cell lines with high expression of MDM2 mRNA, 
MM1s and NCI-H929 (Figure S1B), the p53-responsive miRNAs induced a consistent G0/G1 arrest. This 
effect was observed in ∼30% of scrambled-transfected cells vs ∼60% of the cells transfected with miR-192 
and 215 and ∼45% for miR-194 (Figure 3G,H). By contrast in KMS-28BM cells, retaining WT TP53 but 
expressing lower levels of MDM2 mRNA (Figure S1B), we detected increases of sub-G1fractions (indicative 
of cell death) in cells transfected with miR-192(∼25% sub-G1), 215 (30%) and 194 (12%) at 48 hrs after 
transfection, compared to ∼3% in control cells transfected with the Scr sequence (Figure 3I). At 48 hrs after 
transfection we also detected increased caspase-3 activity (Figure 3J). The differential effect of the miRNAs 
on TP53 WT cells carrying lower MDM2 mRNA basal expression (Figure S1B) led us to analyze MDM2 levels 
after miRNA transfection (Figure S3C). MDM2 mRNA, but not protein, was detected after MM cells 
transfection. Because MDM2 protein is rapidly auto-ubiquitinated and degraded through the proteasome 
pathway (Marine et al., 2010); p53 induction is necessary for its detection in MM cells (Stuhmer et al., 
2006; Ooi et al., 2009). Only in one (Mut TP53 RPMI-8226) of six MM cell lines analyzed, was MDM2 protein 
detected without p53 activation (Figure S1A, S1G). We also noted that MDM2 mRNA was down-regulated 
after ectopic expression of these miRNAs, mostly in WT TP53 cells, but to some extent also in Mut TP53 
cells (RPMI-8226) (Figure S3C). These data were confirmed at the protein level in RPMI-8226 cells where we 
observed ∼20% down regulation of MDM2 protein at 72 hr after miRNA transfection (Figure S3D). The 
results indicate that ectopic expression of miR-192, 215 and 194 in WT TP53 cells inhibits cell growth and 
enhances apoptosis, effects that could be related to MDM2 regulation in MM cells. 
Human MDM2 is a direct target of miR-192, 194 and 215 
The data thus far demonstrate that the biological functions of miR-192, 215 and 194 in MM cells is p53-
dependent. After introduction of these miRNAs the TP53 mRNA level did not change in MM cells but higher 
CDKN1A and lower MDM2 mRNA levels were observed (Figure S3). Both genes, MDM2 and CDKN1A, are 
direct targets of p53 but their expression in this case was not preceded by TP53 transcription (Figure S3B). 
Thus, we hypothesized that miR-192, 194 and 215 could target the expression of MDM2. To further 
examine the effects of these miRNAs on MDM2 protein expression in WT TP53 MM cells, we analyzed the 
consequences of ectopic expression of miR-192, miR-194 and miR-215 at 72 hrs after transfection and 12 
hrs of non genotoxic activation of p53 by Nutlin-3a (10 μM). Increased expression of these miRs upon 
transfection was confirmed by qRT-PCR (Figure S4A), and the effects on p53, MDM2 and p21 levels were 
analyzed by Western blot (Figure 4A). Over-expression of miR-192, 194 and miR-215 significantly increased 
the level of p53 and p21 at 12 hrs after Nutlin-3a treatment compared to Scr-transfected cells (p<0.001), as 
shown by densitometric analysis in Figure 4B,C. Expression of MDM2 protein was dramatically decreased in 
both cell lines (Figure 4A-C). Conversely, knockdown by 2′-O-me-anti-miR-192-194 and 215 (pool) after 12 
hr of Nutlin-3a treatment, as confirmed by qRT-PCR (Figure S4B) in TP53 WT cell lines, increased the level of 
MDM2 protein (p<0.01), while p21 and p53 protein levels were attenuated (p<0.01) (Figure 4B), as 
confirmed by densitometry (Figure 4E). We also confirmed that MDM2 mRNA levels were strongly reduced 
in the miR-192, 194 and 215 transfected cells at 6 and 12 hr of Nutlin-3a treatment in both cell lines 
(Figures 4C). These results indicate that miR-192, 194 and 215 induce the degradation of MDM2 mRNA, 
confirming that they regulate both, protein and RNA levels. We next tested whether MDM2 is a direct 
target of these miRNAs by performing a bioinformatics search (Target Scan [Lewis et al., 2003], Pictar [Krek 
et al., 2005]), but were unable to identify the 3′-UTR of MDM2 as a target. Because the 3′-UTR of MDM2 is 
not well conserved across species, we decided to use the RNA22 target prediction program (Miranda et al., 
2006) which does not need validated targets for training, and neither requires nor relies on cross-species 
conservation. RNA22 predicted two miRNA responsive elements (MREs) for miR-192/215 and two MREs for 
miR-194 in the 3′UTR of human MDM2 (HDM2) (Figures 4D and S4C-S4G). To verify that HDM2 is a direct 
target of miR-192, miR-194 and miR-215, HDM2 3′UTR containing all MREs (∼4K), was cloned into pGL3 
basic construct downstream of the luciferase open reading frame (Figure 4D). This reporter construct was 
used to transfect MM1s cells which express the endogenous miRs following up-modulated p53 expression. 
Increased expression of these miRs upon transfection significantly diminished luciferase expression (Figure 
4D). We subsequently screened the predicted MREs on the 3′UTR of HDM2 mRNA, using luciferase assays 
with 4 different constructs carrying the MREs for miR-192/215 and miR-194 (Figure S4H-S4K). We observed 
that expression of each specific MRE reporter construct was specifically down regulated upon transfection 
of each individual miRNA. Conversely, when we performed luciferase assays using a plasmid harboring the 
binding sites inactivated by site-directed mutagenesis, we observed a consistent reduction in the inhibitory 
effects (Figure S4H-S4K). We also analyzed the expression of MDM2 mRNA in a panel of CD138+ PCs 
obtained from MM patients, MGUS patients and normal donors by RT-PCR (Figure 4E). Through Kruskal-
Wallis analysis we found that MDM2 mRNA is significantly up-regulated in MM samples (p<0.001) 
compared to MGUS samples and normal PCs (Figure 4E). Using non parametric test analysis, we found a 
significant inverse correlation between miR-192 expression and MDM2 mRNA in MM samples (Sperman ρ= 
-0.698, p<0001, n=33) (Figure 4F). 
 
Figure 4 
 
miRNA-192-194 and 215 effect on MDM2 protein and mRNA levels 
miR-192, 194 and 215 re-expression enhances sensitivity of WT TP53 MM cells to non genotoxic 
activation of p53 in vitro and in vivo 
To determine if re-expression of the miRNAs could enhance sensitivity of WT TP53 MM cells to non 
genotoxic activation of p53, we tested MI-219, a highly selective, orally active small-molecule inhibitor of 
the MDM2-p53 interaction (Shangary et al., 2008). We first examined whether MI-219 induces p53, MDM2, 
p21 and Puma up-regulation in MM1s cells after miR-192, miR-194 and miR-215 transfection. In cells with 
forced expression of miR-192 and 215, p53 became detectable even in untreated cells (Figure 5A-5B) 
(p<0.05), confirming previously published data in other cell lines (Georges et al., 2008; Braun et al., 2008). 
p53 re-expression and subsequent p21 and Puma up-regulation was observed in these cells and in miR-194 
transfected cells, and is clearly visible following 24 hrs of 2.5 μM MI-219 treatment (Figure 5A). In control 
cells (Scr) the treatment was ineffective (Figure 5A). Densitometric analysis of p53 and MDM2 protein 
levels was performed when cells were treated for 24 hr with 2.5 μM, 5 μM and 10 μM MI-219 (Figure 5B). 
Confirming our previous data, we observed higher p53 accumulation (≥2-fold increase, p<0.001) and 
dramatic MDM2 down-regulation (≥3-fold decrease, p<0.001) in miRNA transfected cells (Figure 5B). These 
opposing changes in MDM2 and p53 expression levels correlated with higher activation of p53 down-
stream targets, p21 and Puma (Figure 5A). Furthermore, MI-219 induced higher caspase-3 activation in the 
presence of miR-192, miR-194 and miR-215 (p<0.001) (Figure 5C). Next, we examined whether activation of 
p53 by MI-219 leads to apoptosis in MM cells. Indeed, treatment with MI-219 induced apoptosis as 
revealed by Annexin V staining (Figure 5D). In cells transfected with a pool of miRNAs MI-219 effectively 
(p<0.0002) induced apoptosis at 2.5 μM (27±3%), 5 μM (32±3%) while the scrambled control did not. This 
effect was less significant when using MI-219 at 10 μM (30±5%), though it was enhanced when treatment 
was combined with miRNAs (55±5%) (Figure 5D). Increased concentration of MI-219 did not increase the 
apoptotic rate of scrambled-transfected cells but caused non-specific toxicity (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5 
 
miR-192, 194 and 215 increase sensitivity to MI-219 in vitro and in vivo by targeting MDM2 
Because previous studies have shown that MI-219 achieved excellent oral availability, we investigated if, in 
mouse xenograft models, the combined action of miRNAs and oral MI-219 could suppress tumorigenicity of 
MM cells. 8×106 viable MM1s Gfp+/Luc+ cells were injected subcutaneously into the right flank of 40 nude 
mice. At 3 wks after injection a group of 32 mice with comparable tumor size were selected and randomly 
divided into 4 groups for 4 independent experiments, using 8 mice for each combined treatment (Figure 
5E). Specifically, we used the combination of oral treatment with 200 mg/kg MI-219 or vehicle control (VE) 
once a day for 14 days plus direct tumor injection of double strand RNA scrambled sequence (Scr) or a pool 
of pre-miR-192, 194 and 215 (miRs). Whereas the VE-Scr treated tumors increased 2-fold in volume in 2 
wks (from 5390 ± 993 mm3 to 13500 ± 3200 mm3 [p<0.0001]), MI-219/Scr-treated tumors remained static 
in volume (5390 ± 993 mm3 to 5400 ± 1200 mm3) (Figure 5E). By contrast, mice treated with VE-miRs 
showed ∼1.5-fold reduction in tumor size (from 5390 ± 993 mm3 to 3700 ± 950 mm3 [p<0.01]). The most 
effective combination was MI-219 plus miRs, where mice showed 5-fold reduced tumor volumes (from 
5390 ± 993 mm3 to 2100 ± 560 mm3 [p<0.01]) and >93% reduction when compared to VE/Scr treatment 
(Figure 5E). These findings demonstrate proof-of-concept for in vivo therapy of MM using combined 
miRNAs and an MDM2 pharmacological inhibitor. 
miR-192 and miR-215, by antagonizing MDM2 down-regulation, target IGF-1 and IGF1-R 
Since our data demonstrate that miR-192, miR-194 and miR-215 target MDM2, we sought to determine if 
MDM2 substrates could also be affected. IGF-1R is a known target of MDM2 ubiquitin ligase function 
(Girnita et al., 2003; Froment et al., 2008). Therefore, by targeting MDM2, miR-192, 194 and 215 may 
indirectly influence the expression of IGF-1R. In MM cells, IGF-1R and its ligand, IGF-1, are key factors in 
regulation of PC migration into the bone marrow (Qiang et al., 2004; Tai et al., 2003). We noted that in WT 
TP53 MM cells, p53 re-expression was strongly associated with down-regulation of IGF-1R and IGF-1 (Figure 
S5A and S5B) compared to mutant TP53 MM cells (Figures S5C and S5D). We sought to determine the 
effect of miRNAs on IGF-1R and IGF-1 expression through targeting MDM2. We found that in the presence 
of miR-192, 215 but not miR-194, IGF-1R and IGF-1 protein levels decreased, as determined by Western 
blot analysis (Figure 6A). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6 
 
 
miR-192-215 regulate IGF-1 and IGF1-R expression in MM cells 
Furthermore, inhibition of endogenous miR-192/215, using antisense oligonucleotides, combined with 24 
hrs of Nutlin-3a treatments increased both IGF-1R and IGF-1 levels in MM1s cells (Figure 6B). This effect 
was not seen with miR-194. To determine if the regulation of IGF-1 does affect IGF1R in MM cells, we 
silenced IGF-1 and observed up-regulation of IGF-1R protein levels at 48 and 72 hrs post treatment (Figure 
6C). This effect was clearly different from that observed following miRNA transfection (Figure 6A). We next 
tested whether miR-192 and 215 target IGF-1R and IGF-1 directly by generating luciferase reporters 
containing their 3′ UTRs. Using Targetscan (Lewin et al., 2003) Pictar (Krek et al., 2005) and RNA22 (Miranda 
et al., 2006) searches we, identified several MREs for miR-192 and miR-215 but not for miR-194 in the 
3′UTR of IGF-1R and IGF-1R mRNAs (Figures 6D,E). Luciferase activity dropped 40–50% when these 
constructs were co-transfected into MM1s cells with miR-192, 215 compared to miR-194 and Scr (Figures 
6D, 6E, S5E-S5I). To determine if in freshly isolated CD-138+ PCs these miRNAs could regulate IGF-1 and 
IGF-1R expression, we transfected miR-192 and 215 (pool) into PCs of 9 patients and we performed 
immunofluorescence analysis for IGF-1R and IGF-1 at 48 hrs. We observed a significant decrease in IGF-1R 
and IGF-1 protein expression (Figures 6F,G). Transfection efficiency was confirmed using RNA Fluorescent 
Oligo (Figure 6H). These results indicate that miR-192 and miR-215 directly target IGF-1R and IGF-1 in MM. 
miR-192 and 215 block MM migration and invasion in vitro and in vivo 
Given the known role of IGF-I and IGF-1R as anti-apoptotic factors and in MM migration through 
endothelial barriers and bone marrow stroma (Qiang et al., 2004; Tai et al., 2003), we sought to determine 
if miR-192 and 215 interfere with the chemotactic function of IGF-I and block migration and invasion of MM 
cells. We first determined that miR-192 and 215 actions on the IGF-1 axis in MM affect both WT TP53 
(MM1s) and mutant (RPMI-8226) cell lines (Figure 7A) and that the down-regulation of both proteins 
critically affects S6 and AKT phosphorylation in these cells. Next, we found that ectopic expression of miR-
192 and 215 in NCI-H929 and RPMI-8226 IGF-1 treated cells was associated with significant decrease in cell 
adhesion (Figure S6A,B), migration and tissue invasion compared to Scr control. To this end, we used an 
intra-epithelial trans-well migration assay with IGF-1 at various concentrations as attractant and two bone 
marrow-derived stromal cells, HS-5 (fibroblastlike) and HS-27A (epithelial-like) as cell layer. As shown in 
Figures 7B and S6C, IGF-1 (50 ng/ml) stimulated migration of MM cells, MM1s and RPMI-8226. To further 
examine the role of miRNA-192, 215 and 194 in MM cells, we investigated the effect of these miRNAs on 
migration in vivo, using a previously described homing model (Roccaro et al., 2008). Nine NOD-SCID mice 
(for each group) were intravenously injected with 8×106 of pre-miRNA-192–, 194 and 215 or Scr probe–
transfected GFP+/Luc+MM1S cells. One week later, mice were injected intravenously every week for 4 
weeks with an individual miRNA or Scr dissolved in PBS (10 μg for each mouse). After 5 wks the homed and 
proliferated tumors were markedly suppressed in miRNA-treated mice compared to Scr-transfected MM 
cells (p<0.01) (Figure 7C). At 5 wks post-injection we first noted reduced tumor progression, by 
bioluminescence imaging (Figure 7D). Mice injected with Scr–transfected MM1s in addition to serial iv-
injection with Scr showed significant tumor growth, but tumor burden was significantly reduced in mice 
injected with pre-miR-194 and was nearly nonexistent in mice injected with either pre-miR192 or pre-miR-
215 (Figure 7C,D). In addition, through FACS analysis using human CD-138+ antibody we analyzed bone 
marrow engraftment of these cells in injected NOD-SCID mice. We confirmed that Scr-treated mice showed 
bone marrow engraftment of ∼25±15% of MM1s cells vs 4±2% for miR-192 and 2±2% for miR-215 animals 
(Figure 7E). The in vivo action of miR-194 was less effective, 12±3% of bone marrow engraftment MM1s 
cells compared to miR-192 and 215 but still higher than the Scr control (Figure 7E). These data indicate that 
miR-192, 215 but also miR-194 have therapeutic potential not only by affecting proliferation rates in MM 
cells but also by affecting the homing and migration ability of MM cells. 
 
 
 
Figure 7 
 
 
miR-194, 215 and 194 block invasion ability of MM cells 
Discussion 
Complex cytogenetic abnormalities and numeric chromosomal aberrations occur in virtually all multiple 
myeloma, and in most, if not all, cases of MGUS (Kuehl and Bergsagel, 2002). Paradoxically, mutations 
and/or deletion of TP53 occur in only a small percentage of intramedullary MMs and not at all in MGUS 
(Chng et al., 2007). Several reports (Teoh et al., 1997; Quesnel et al., 1994) and our data (Figure 4E) suggest 
that MDM2 over-expression in MMs, but not its gene amplification (Quesnel et al., 1994), could be 
responsible for p53 inactivation in cells retaining functional p53 pathways. This supports the idea that 
induction of p53 in this setting might be a suitable treatment for MM. There have been a few reports 
concerning microRNA deregulation in MM and although not all reported findings were in agreement, they 
confirmed that such deregulation is important in MM pathogenesis (Pichiorri et al., 2008; Roccaro et al., 
2009; Lionetti et al., 2009; Gutierrez et al., 2010). Here, we studied the role of miRNAs in the p53 apoptotic 
pathway upon non genotoxic activation of p53 in MM cells, using small molecular inhibitors of MDM2 
(Nutlin-3a, MI-219). Upon p53 activation we identified two related microRNA clusters located in regions 
considered important for MM (miR-194-2-192 at 11q13.1 and miR-194-1-215 at 1q41.1) (Fonseca et al., 
2009). Furthermore, the knowledge that miRNAs coming from the same cluster can reinforce their action 
on the same cellular pathways (Garofalo et al., 2009; Ventura et al., 2008), led us to study the molecular 
mechanisms associated with activation of the p53 pathway by these miRNAs. Through characterization of 
the miR-194-2-192 cluster promoter region and definition of a non canonical p53 consensus site we have 
shown that these miRNAs are direct p53 targets. In patient samples the expression of these miRNAs 
changed during transition from normal PC, via MGUS to intramedullary MM; these miRNAs were 
significantly down-regulated in a cohort of newly diagnosed MMs vs MGUS; miR-192, 215 and 194 
enhanced colony suppression, cell cycle arrest or apoptosis in a p53-dependent manner. We also noted, as 
in the case of KMS28BM cells, that their biological action could be associated with the MDM2 status in MM 
cells. The short half-life of MDM2 protein (Marine et al., 2010) and difficulties in analyzing its protein 
expression in MM cells without p53 activation, led to the demonstration that the effect of these miRNAs on 
MDM2 was clearly detectable after treating WT TP53 MM cells with combined Nutlin-3a and ectopic 
expression of the miRNAs. In fact, we observed that in treated cells with enforced expression of these 
miRNAs MDM2 was dramatically down-regulated at protein and mRNA levels and this down-regulation was 
inversely associated with higher p53 expression and p21 activation (Figure 4A-4C). Luciferase assays using 
plasmids harboring the MDM2 3-UTR sequence strongly confirmed that MDM2 is the direct target of these 
miRNAs. In a subset of newly diagnosed MMs, elevated levels of MDM2 mRNA were inversely associated 
with miR-192 expression. We proved, in vivo and in vitro, that the combination of these miRNAs with p53 
pharmacological activator (MI-219), leading to MDM2 down-regulation and subsequent p53, p21 and Puma 
up-regulation, could be a successful therapeutic strategy. In fact it produced anti-tumor results that could 
not be achieved solely by increasing the drug concentration. We also found that miR-192 and miR-215 
expression, by overriding MDM2 ubiquitination of IGF-1R (Girnita et al., 2003; Froment et al., 2008), 
directly targets the IGF-1 axis in MM cells, controlling mobility and invasive properties of MM cells in vitro 
and in vivo. We propose a model in which these miRNAs are: 1) regulators of the auto-regulatory loop, 
increasing the window of time between p53 apoptotic action and p53 degradation by MDM2; and 2) at the 
same time targeting the IGF axis, antagonizing the MDM2 ubiquitin ligase function on IGF-1R (Figure 8). 
 
 
 
 
 
 
Figure 8 
 
miR-192, 215 and 194 impair the p53/MDM2 auto-regulatory loop 
During Nutlin-3a treatment of primary CD-138+ PCs from MMs without TP53 deletion, we noted that p21 
activation, as well as re-expression of the three miRNAs, was consistent but not uniform in all samples 
analyzed. Possibly mechanisms other than alterations to the TP53 gene could influence the sensitivity to 
MDM2 molecular inhibitors. In seeking an explanation for the lack of expression of these miRNAs in MMs, 
we noted that the genes for these miRNAs are located in chromosomal regions in MM that are normally 
characterized by chromosome gain and translocations rather than deletions (Fonseca et al., 2009). We 
then, explored the methylation status in the promoter of the miR-194-2-192 cluster. By combined bisulfite 
restriction analysis (COBRA) we detected hypermethylation of the promoter region of this cluster (Region 
R) (Figure S7A) in MM cell lines (Figure S7B). Furthermore, treatment of MM cell lines with a demethylation 
agent (Azacytidine) increased the expression of these miRNAs in WT TP53 MM cell lines (Figure S7C). Re-
expression of the SOCS-1 gene, known to be silenced by hypermethylation in MM cells (Galm et al., 2002), 
served as internal control. 
It is likely that the transition from MGUS to MM is favored by clonal selection of cells with aberrant 
promoter methylation of the miR-194-2-192 cluster. This could be associated with a decreasing ability of 
p53 to down-modulate MDM2 expression thus tipping the regulatory balance in favor of MDM2 in MM 
cells. This proposed model (illustrated in Figure S7D) will require further investigation. 
Of note, monoallelic deletion of TP53 in MM, which often seems to occur without mutation on the other 
allele, is associated with an extremely poor prognosis (Chng et al., 2007). This supports the idea that a two-
fold decrease in TP53 gene content is associated with tumor progression, which supports the hypothesis 
that a partial lack of expression of these miRNAs in MMs could create a p53 imbalance with direct biological 
consequences. 
In summary, our results have defined a mechanism of p53 regulation through miRNAs acting on MDM2 
expression, providing the basis for the development of miRNA-targeted therapies for MM, as illustrated in 
Figure 8. 
Experimental Procedures 
Collection of primary cells 
33 newly diagnosed primary MM samples, 14 primary samples from monoclonal gammopathy of 
undetermined significance (MGUS), and 5 primary samples from healthy donors were obtained from bone 
marrow aspirates. Written informed consent was obtained in keeping with institutional policies (IRB-
approved procurement protocol (2000C0247) at The Ohio State University and The University of Turin 
GIMEMA-MM-03-05, N. EUDRACT 2005-004745-33). Three of the five healthy PCs used were purchased 
from AllCells LLC. (Emeryville, CA). 
Luciferase Assays 
MM1s cells were cotransfected with 1 μg of pGL3 firefly luciferase reporter vector (see luciferase reporter 
vector method supplementary information), 0.1 μg of the phRL-SV40 control vector (Promega), and 100 nM 
miRNA precursors (Ambion) using nucleoporation (LONZA) Cell Line Nucleofector Kit V as previously 
described. Firefly and Renilla luciferase activities were measured consecutively by using the Dual Luciferase 
Assay (Promega) 24 hr after transfection. Each reporter plasmid was transfected at least twice (on different 
days) and each sample was assayed in triplicate. 
Mouse experiments 
Animal studies were performed according to institutional guidelines. 1 × 106 of GFP/Luc + MM1s cells were 
suspended in 0.10 ml of extracellular matrix gel (BD Biosciences) and the mixture was injected 
subcutaneously into the right flank athymic nu/nu mice. 3 wks after injection, mice with comparable size 
tumors were treated for 2 wks with a combination of oral dose of MI-219 (200 mg/kg) or vehicle, once a 
day for 14 days and miRNAs or scrambled sequence oligos (10ug) (Ambion), was injected directly into the 
tumors once a week for 2 wks. For the NOD-SCID engraftment model Luc+/GFP+ MM.1S cells (8 × 
106/mouse) were injected into the tail vein of SCID mice (. Treatment started 7 days from tumor cell 
inoculation, by weekly i.v. injections of miRNAs or scrambled sequence. RNA oligos (Ambion) (10 μg) for 
four cycles (4 wks total). For more details see in vivo experiments supplemental data. 
Transfection method for primary cells and MM cell lines 
CD-138+ PCs obtained from new diagnosed MM patients and isolated as previously described were 
transfected by using nucleoporation (LONZA) Cell Line Nucleofector Kit V (Cat#VCA-1003). MM1s, NCI-H929 
cell lines were transfected by using using nucleoporation (LONZA) Cell Line Nucleofector Kit V (Cat#VCA-
1003). Instead for U266, KMS-28BM and RPMI-8226 Cell Line Nucleofector Kit C (Cat#VCA-1004) was used. 
Specifically for primary cells 1 ×106 CD-138+ PCs were resuspended in 100 μl of V solution and 100 nM 
miRNA precursors (Ambion) was used for the transfection reaction. For more details see transfection 
method for primary cells supplemental information. 
Target Screening 
In this study, we used three publicly available search engines for target prediction to obstain the putative 
targets: TargetScan (Release 2.1), http://genes.mit.edu/targetscan, Pictar,http://pictar.bio.nyu.edu and 
Rna22, http://cbcsrv.watson.ibm.com/rna22_targets.html. For RNA22 predicted sites we considered only 
the heteroduplex with a folding energy >-27 Kcal/mol (Figures S8B-8E) because we were not able to 
confirm by luciferase assay the interactions between target gene and miRNAs with a folding energy less 
that -27 Kcal/mol (data not shown). 
Array data 
Data deposition 
The microarray data have been deposited in the Array Express database, www.ebi.ac.uk/arrayexpress 
(accession no. E-TABM-1037 and E-TABM-1038). 
Supplementary Material 
Figure S1. miR-34a, miR-194 and miR-192 expression are related to TP53 status in MM cells. (A-B) p53 and 
MDM2 expression in MM cell lines used for microarray experiments A) 80 μg of whole cell lysate of MM cell 
lines used for microarray experiments, were subjected to Western blot analysis using p53, MDM2 and 
Gadph antibodies B) MDM2 mRNA levels in MM cell lines carrying WT TP53 compared to normal PCs (N=4). 
Relative expression of MDM2 mRNA in MM1s, NCI-H929 and KMS28BM cell lines compared to the average 
MDM2 mRNA expression of 4 normal PCs. The PCR products for the MDM2 gene were normalized to 
GAPDH mRNA expression. Values represent mean ± SD from three experiments. (C) miR-34a, miR-194 and 
miR-192 relative expression in WT TP53 (MM1s, NCI-H929, KMS28BM) and Mutant/Null TP53 cells (RPMI-
8226; U266, JJN3) measured by q-RT-PCR. Bars represent relative fold changes, expressed in 2ˆ-(ΔCT) values 
±SD obtained from three independent experiments. RNU44 expression was used for normalization. (D) 
Kinetics of activation of miR-15a, 29a and 29b in MM 1s cells upon Nutlin-3a treatments, measured by qRT-
PCR and Northern blot analysis. Lines represent relative fold changes, expressed in 2ˆ-(ΔCT) values ±SD 
obtained from three independent experiments. RNU44 expression was used for normalization for the qRT-
PCR experiments and RNU6 for the northern blot analysis. (E) Time course of MYC mRNA expression in 
Nutilin-3a treated MM 1s cells by RT-PCR. The PCR product was normalized to ACTIN mRNA expression. 
Values represent mean ± SD from three independent experiments. (F-K) miR-192, miR-194 and miR-215 re-
expression is dependent on p53 activation. Western analysis for p53, MDM2 and Gapdh in NCI-H929 (WT 
TP53) (F), RPMI-8226 (Mut TP53) (G) and U266 (Mut TP53) (H) cell lines after different times of Nutlin-3a 
treatment. All experiments were performed in triplicate. Stem loop q-RT-PCR showing the time course of 
miR-192, 194, 215 and 34a expression in NCI-H929 (I) RPMI-8226 (J) and U266 (K) cells Nutlin-3a treated 
compared to DMSO treatment The PCR products were normalized to RNU6B expression. Bar-graphs 
represent mean values observed in four separate studies ± SD. L) Representative fax analysis of purified CD-
138+ plasma cells with purity more than 90% using passive selection method (Stem-Cell) from primary 
samples that we used for our experiments ±SD (33 MM and 14 MGUS patients). MM1s cells were used as 
positive control and the non selected cells as the negative control. M) Western analysis showing p53 and 
MDM2 expression after Nutlin-3a overnight treatment in 3 different patients, 2 with TP53 deletion (Pt-1 
and Pt-2) and 1 with WT (Normal) TP53 (Pt3). CDKN1A mRNA expression by RT-PCR in CD-138+ PCs 
obtained from 8 different patients (Pt-1-Pt-8 Table S3) after 12 h of Nutlin-3a treatment (N). The PCR 
product was normalized to ACTIN mRNA expression. The bar-graph represents the mean values observed in 
four separate studies ± SE. (O) miR-194, miR-192, miR-215 and miR-34a expression in primary tumor 
samples, after Nutlin-3a treatment, measured by stem loop qRT-PCR. Lines represent relative fold-changes 
between DMSO and Nutlin-3a treatment. Stem loop q-RT-PCR values were normalized to RNU44 
expression. The bar graphs in Figure C and D are representative of the 8 samples used for primary culture 
and Nutlin-3a treatments. Values were normalized to RN U44 expression. The bar graph in Figure N and O 
are representative of 8 samples used for primary culture and Nutlin-3a treatments. Values represent mean 
± SD from three experiments. 
Figure S2. p53 interacts with p53 consensus sequence up-stream of miR-194-1-215 cluster on chromosome 
1(q41) in MM cells. Chip assay with anti-p53 or normal IgG from the same animal after 24 hr of p53 non 
genotoxic activation, revealed binding of p53 to the miR-194-1-215 cluster promoter in vivo in MM1s cells. 
ChIP primers were designed to amplify the region containing the putative p53 binding site in the pri-miR-
194-1-215 promoter (-2.7 kb from the cluster). p53-responsive CDKN1A gene promoter associated with p53 
was used as positive control, whereas amplification of a MT-RNR2 gene portion yielded very little 
background signals and served as negative control. 
Figure S3. miR-192, 194 and 215 regulate CDKN1A and MDM2 mRNA levels in MM cells. (A-C) MM1s, NCI-
H929, KMS28BM and RPMI-8226 cells (pre-miRNA-192, 194, 215, Scr sequence– transfected) were 
harvested at 48 hr after transfection and CDKN1A (A), TP53 (B) and MDM2 (C) mRNA expression level was 
assessed. The PCR products for the genes were normalized to ACTIN mRNA expression. The bar-graphs 
represent mean values observed in four separate studies ± SD. (D) miRNA-192-194 and 215 effects on 
MDM2 protein level in Mut TP53 cells (RPMI-8226). RPMI-8226 cells (miRNA-192, 194, 215, Scr sequence-
transfected) were harvested at 72 h after transfection. Whole cell lysates were subjected to Western blot 
using MDM2 and Gapdh antibodies. Bars indicate MDM2 protein relative fold change ±SD. Gapdh was 
internal loading control and used for the densitometry analysis. The experiment was performed in 
triplicate. 
Figure S4. miR-192, 194 and 215 target human MDM2 (HDM2). (A-B) Assessment of expression of miRNAs 
in MM transfected cells using pre-miR-192, 194 and 215 and anti-sense oligo-nucleotides (ASOs). MM1s 
and NCI-H929 cells transfected with pre-miRNAs (A) or ASOs. (B) were harvested at 72 hr after transfection 
and the level of the microRNAs was assessed by stem loop q-RT-PCR for each miRNA compared to the Scr 
sequence-transfected cells. Bar-graphs represent the mean values observed in four separate studies ± SD. 
C) Representation of the full length human MDM2 mRNA (HDM2) D-G) miRNAs predicted to interact with 
HDM2 mRNA at several consensus binding sites in its 3′-UTR, according to “in silico” RNA-22 prediction 
software with a folding energy > -27 Kcal/mol. The MREs are indicated by the triangles. (H-K) Luciferase 
assay showing decreased luciferase activity in cells co-transfected with pGL3-MDM2-3′UTR containing the 
specific binding sites (∼1 kb) for each miRNA. Specifically: CS2117 and CS5974 constructs for miR-194 (H-J) 
and CS3975 and CS6360 constructs for miR-192 and 215 (I-K). Deletion of six bases in all putative consensus 
sequences abrogates this effect (Del). Bars indicate firefly luciferase activity normalized to Renilla luciferase 
activity ± SD. 
Figure S5. miR-192 and 215 target IGF-1and IGF-1R in MM cells. A-D) Effect of Nutlin-3a treatment on IGF-R 
and IGF-1 protein expression in MM cells with different TP53 status. WT TP53 (MM1s and NCI-H929) (A-B) 
and Mutant TP53 (RPMI-8226 and U266) (C-D) cells were treated with Nutlin-3a (10 μM) or DMSO vehicle 
and whole cell lysates collected at different time points were immunoblotted using antisera against IGF-1R, 
IGF-1, p53, MDM2. Gapdh was used as loading control. A decrease in IGF-R and IGF-1 protein level is shown 
only in TP53 WT cells upon Nutlin-3a treatment. E) Representation of the full length IGF-1R mRNA. F-G) 
miRNAs predicted to interact with IGF-1R gene in several consensus binding sites at its 3′-UTR, according to 
“in silico” RNA-22 prediction software with a folding energy > -27 Kcal/mol. H-I) Luciferase assay showing 
decreased luciferase activity in cells co-transfected with 2 different constructs (1 kb each) of pGL3-IGF-1R-
3′UTR and miR-215 (H-I) and miR-192 (I) but not with miR-194 and Scr sequence (H-I). Deletion of six bases 
in all putative consensus sequences abrogates this effect (Del) (H-I). Bars indicate firefly luciferase activity 
normalized to Renilla luciferase activity ± SD. 
Figure S6. miR-192 and 215 affect the ability of MM cells to adhere and migrate in response to IGF-1. (A-B) 
MM1s and RPMI-8226 cells (pre-miRNA-192, 194, 215, Scr sequence–transfected) at 48 hr after 
transfection were harvested, treated with calcein and incubated with IGF-1 (50 ng/ml) and their ability to 
adhere to fibronectin plates was assessed by fluorescence assay. MM1s (A) and RPMI-8226 (B) with ectopic 
re-expression of miR-192, 215 and also miR-194 lost their ability to respond to IGF-1 treatment compare to 
Scr sequence. (C) Intra-epithelial migration assay in MM1s and RPMI-8226 cells (pre-miRNA-192, 194, 215, 
Scr–transfected) using HS-27A stromal cell as cellular layer at different concentrations of IGF-1 as 
attractant. Bars indicate relative fold change of migration compared with the control. All experiments were 
performed in triplicate ± SD. 
Figure 7. The promoter region of miR-194-2&192 is methylated in MM cell lines. (A) Representation of the 
genomic region of miR-194-2&192 obtained from University of California Santa Cruz genome browser 
(2006). The red arrow is the region that we analyzed for the methylation study, including the p53 consensus 
sequence. (B) Combined bisulfite restriction analysis (COBRA) in 9 MM cell lines. Universal methylated DNA 
from Millipore was used as positive control and normal CD-138+ plasma cells as negative control. The 
digestion of PCR products coming from methylated DNA was carried out with TaqI for the region R. (C) 
stem-loop q-RT-PCR for miR-192 and miR-194 and RT-PCR for SOCS-1 genes normalized to RN44 and ACTIN 
respectively, expressed as fold increases after 3 days of treatment with 5-Azacitidine (10 μM) compared to 
DMSO treated cells. All experiments were performed in triplicate. ± SD. (D) Illustration of the p53—miR-
192,194,215 —MDM2 auto regulatory loops, showing the central role played by the miRs in determining 
the balance of p53 suppressor and the MDM2 oncoprotein expression levels. 
Table S1. miRNAs differentially expressed between WT TP53 versus Mutant TP53 MM cell lines. Related to 
Figure 1 
Table S2. miRNAs differentially expressed between MM 1s cells Nutlin-3a treated versus MM1s cells DMSO 
treated. Related to Figure 1 
Table S3. Patient samples clinical data. Related to Figure 1 
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